Drug Trial Radar · NCT02779699
A Study of AL2846 on Tolerance and Pharmacokinetics
Last checked: Nov 19, 2026Latest source record: May 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
May 2016
Primary completion
Oct 2020
Study completion Oct 2020
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of AL2846,a C-met/Hepatocyte growth factor tyrosine kinase inhibitor,in patients with advanced cancer.
Conditions
- Advanced Cancer
Interventions
AL2846Drug
AL2846 p.o. qd
Primary outcomes
What the sponsor says the trial is designed to measure.
- The type of dose-limiting toxicity(ies) (DLT[s]) of AL2846Time frame: For 4 weeks for DLTs
- Pharmacokinetics of AL2846 (in plasma)Time frame: up to 28 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)
- The maximum tolerated dose (MTD) of AL2846Time frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.